InvestSMART

Vitrafy Life Sciences Limited (ASX:VFY)

ALERT: Price-sensitive ASX Announcement for VFY
Current share price for VFY : $3.740 0.04 (1.08%)+
Announcement
Release
4 Aug 2026 8:23AM
Price at Release
$3.700
Full Release
download
Summary
In the fiscal year 2026, Vitrafy Life Sciences Limited achieved significant milestones across product development, market expansion, and operational execution. The company successfully expanded into the U.S. market, establishing strategic foundations and securing partnerships with blood collection organizations like Vitalant and Hoxworth. Vitrafy reported a 94.4% post-thaw platelet recovery rate in its USAISR Phase II study, surpassing both U.S. and European standards, leading to commercial traction in the blood sector. The company also progressed in the cell and gene therapy (CGT) market, engaging with manufacturers and developers, and anticipates first revenue-generating contracts in FY27. Financially, Vitrafy raised $30 million, enhancing its cash position to $41.2 million by year-end. The company is set to capitalize Guardion devices on its balance sheet starting FY27, with plans for further expansion and operational scaling in the U.S.
Key Points
  • Executed key milestones across product, market development, and operations.
  • Established U.S. market foundation and strategic partnerships.
  • Achieved 94.4% post-thaw platelet recovery in USAISR Phase II study.
  • Expanded blood sector commercial traction through key agreements.
  • Advanced CGT market engagement, anticipating first revenue in FY27.
  • Strengthened financial position with $41.2 million in cash and term deposits.
  • Prepared to capitalize Guardion devices to balance sheet in FY27.
  • Focus on scaling U.S. operations and expanding market reach.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.